Preclinical Antileukemia Activity of Tramesan: A Newly Identified Bioactive Fungal Metabolite

Figure 4

TR induces a dose- and time-dependent reduction in cell count in primary cells from AML patients. AML primary cells were exposed to the indicated concentrations of TR. Cell counts and viability were assessed for the individual sample after 72–120 h and 144–168 h by trypan blue exclusion.